ThinkstockThere’s no doubt that great strides have been made in Americans’ health over the years. Americans smoke less, are more likely to be insured and live longer. However, significant health disparities remain across the…
Shares of Mylan retreated first thing Monday morning, after the generic drugmaker's sweetened bid for Swedish drugmaker Meda was rejected.
The NYSE Arca Biotechnology Index fell nearly 9% between a peak on Jan. 22 and a low on Feb. 5. It jumped 23% over the next three weeks, and then gave it all back…
Eli Lilly reported disappointing first-quarter 2014 results before markets opened Thursday, due in part to the impact of U.S. patent expirations for Cymbalta and Evista. Shares were up in premarket trading.
ThinkstockBy any stretch of normal measurement in earnings season, Gilead Sciences Inc. (NASDAQ: GILD) should have been a rocketing stock on Wednesday. Gilead blew away earnings and revenue estimates. Its Sovaldi Hepatitis C drug…
The market for initial public offerings was getting to be a bit ridiculous. Now that volatility has returned in the broader stock market, a reality check is starting to be seen as more IPOs…
24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in hand, while others have pending FDA approval verdicts.
In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are making major advances in cancer therapeutics. Here is the UBS list of stocks that…
ThinkstockGilead Sciences Inc. (NASDAQ: GILD) and Amgen Inc. (NASDAQ: AMGN) have both reported earnings. This is a definite difference in how the reports look, and it could throw a wild card report for the…
ThinkstockBiotech stocks took it on the chin during the sell-off. In fact, biotech stocks may have even led the sell-off of momentum stocks in a reality check. The problem is that after years of…
GW Pharmaceuticals is far from your typical pharma or biotech stock. It is also far from your typical legalized marijuana or medical marijuana stock. And shares surged on a pair of endorsements.
The specialty pharmaceutical sector is exploding with news of takeovers, exchanges and possible mergers. Here are some of the top stocks started with a rating of Buy at Jefferies.
ThinkstockIt is not that common that you hear about mergers in the $50 billion range. But what about when you hear of mergers in the $80 billion or $100 billion range? AstraZeneca PLC (NYSE:…
Shares of Sarepta Therapeutics went through the roof Monday morning following an announcement that it plans to have a New Drug Application filed with the FDA by the end of 2014 for its muscular…
In a new research report, the J.P. Morgan health care team highlights their top names to buy after the sell-off that may provide investors some incredible outsized gains over the rest of the year.